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In Germany since 1980, more than 300 dinical studies have been carried out with standardized
phytopharmaceuticals, including Cratagu, Silybum, Ginkgo, Hj>peicwm, Sabal Urtica, Kava-
Kava,Alliumsativum, Valerian Aesdue% Echinamaw and Viscumdnrg. Thesestudiesassessed the
efficacy ofphytopharmaceuticals for the treatment ofmoderate or modeatel severe diseases and
prevention. Several comparative clinical tals showed that these phytopharmaccutical had fill
therapeutic equivalence with chemotherapeutics and had the simultaneus advantage of being
devoid ofanyadverse efcts. The mechanism ofaction ofherbal drugs and their extract prepara-
tions, whichdiffer inmanyrespects from that ofsyntheticdrugs ormono substances, can be char-
acterized as a polyvalent action and interpreted as additive or, in some cases, potentiating.
Currentty, arationale for theobserved reersal effcs and optimal effects withverylowdoses after
along-term application. has not been developed, but is under investigation by systematic research
at the molecularlevel. Keywontc Germany, phytomedicine research, phytopharmacology, quality
proof of phytopharmaceuticals. Environ Health Perspect 107:779-781 (1999). [Online
25August 1999]
bep://ehpnetl.niebs.nih.gov/docs/1999/107p779-781wagner/abstracthtml
In Germany, there are two reasons phy-
topharmaceuticals are of high standard and
are classified primarily as conventional drugs
by law. One reason is that during the last 50
years traditional medicine has been kept alive
by both medical practitioners and the
increasing interest ofpatients in herbal drugs.
The other reason is that shortly after World
War II the pharmaceutical industry special-
ized in and relied on herbal drugs and also
developed and supported projects aimed at
optimizing the quality of herbal drugs by
standardization and scientific basic research.
This development was paralleled by an inten-
sified evaluation ofherbal drugs and a search
for the active principles ofphytopreparations.
The fight for the acceptance and registra-
tion of phytopharmaceuticals as drugs has
been successful. Today in Germany most of
the herbal drugs, even mixtures of herbal
drugs, are registered as conventional drugs
(1); this means that they meet the same strin-
gent criteria ofquality, efficacy, and safety as
synthetic drugs. These requirements of the
German drug law has stimulated the search
for the active principles in medicinal plants
and phytopreparations, the development of
standardization methods of phytoprepara-
tions, and theperformance ofclinical trials.
The search for the active principles was an
important prerequisite for the standardization
procedure. In contrast to investigations car-
ried out 10 or 20 years ago, most extract frac-
tionations were performed using bioguided
methods and the diode array high-perfor-
mance liquid chromatography (HPLC) tech-
nique (2,3). These techniques may be quickly
performed and allow researchers to focus on
those fractions or compounds that are expect-
ed to be responsible for the pharmacologic
activity ofan herbal drug. Because ofthe use
ofnew target models in pharmacology, there
has been remarkable progress in determining
the mechanisms ofaction and the true active
constituents ofherbal drugs. Forexample, the
well-known antitumor activity of garlic
derives partly or totally from apoptosis
induced by reactive oxygen species via the
transcription nuclear factor KB of the tumor
cell (4). In another experiment, Dirsch et al.
(5) revealed that allicin and ajoene, the major
constituents of fermented garlic extracts,
inhibit the nitric oxide-synthase of macro-
phages and, by this, the generation of NO
species, which in turn may be involved in the
pathophysiology of atherosclerosis. In a new
approach to elucidate the antiprostatic active
principle of the roots of Urtica dioica (sting-
ing nettle) root, we showed that one major
constituent in the water extract ofthis herbal
drug, the Urtica lectin UDA (Urtica dioica
agglutinin), binds to the epidermal growth
factor receptor of the prostatic cell and thus
inhibits prostategrowth (6).
Further insights into the mechanisms of
action ofherbal drugs have been obtained by
novel bioguidedphytochemical investigations
with Echinacea, Hypericum, and Crataegus
drugs (7-9). In many cases, the overall phar-
macologic effects and therapeutic efficacies
derived not from a single compound but
from several compounds generating additive
or synergistic pharmacologic effects. This
means that the standardization method to be
applied should include at least two or more
compounds according to methods estab-
lished by the national pharmacopoeias or
additional specific herbal drug monographs.
Because the criteria for the qualityproofofan
herbal drug differ from country to country,
steps should be taken toward a global harmo-
nization of the guidelines, e.g., by the
International Federation of Pharmaceutical
Manufacturers Association (IFPMA), which
represents the global research-based pharma-
ceutical industry and aims to ensure the same
standards of safety, quality, and efficacy for
newmedicines and more efficient registration
for use worldwide. These endeavors are
handicapped when the active principles are
only partly known or when a mixed prepara-
tion contains several raw drugs or extracts. In
this case, a fingerprint chromatogram of the
extract or preparation obtained by HPLC,
gas chromatography (GC), or thin-layer
chromatography (TLC) is the most appro-
priate way to document the quality (3). This
fingerprint should demonstrate identity and
purity of a drug and should guarantee the
therapeutic equivalence of extracts from the
same herbal drug. Single marked con-
stituents can be quantified. An exact chemi-
cal characterization ofall major constituents
ofan extract can only be achieved by specific
and selective analytical methods such as
HPLC with diode array detection, HPLC-
mass spectrometry, or capillary GC with
mass detector. If a phytopreparation con-
tains more than four or five drugs or
extracts, it is more reliable to characterize the
individual drugs or extracts by HPLC before
mixing them. For publication and registra-
tion of phytomedicines in Germany, it is
mandatory that pharmacologic experiments
be performed with at least two or three
batches ofthe phytopreparation from differ-
ent time periods to confirm reproducible
processing and to guarantee stability and the
sameefficacy ofthe preparation.
Before initiating a clinical trial, all toxici-
ty studies necessary to establish the safety of
the trial must be performed. From 1970 to
1985, the first phase of herbal drug investi-
gations in Germany was completed; this
involved proving quality of these phyto-
preparations and a thorough search for the
various active principles. This phase was fol-
lowed by clinical trials that initially focused
on about 10 herbal drugs or phytoprepara-
tions which were already on the market, but
for which sufficient good clinical practice
studies were lacking.
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The herbal drugs include
* Hawthorn leaf with flower (Crataegus
monogyna, C. laevigata)
* Garlic (Allium sativum)
* Ginkgo bilobaleaf
* St.John's wortherb (Hypericumperforatum)
* Valerianaroot (Valerianaofficinalis)
* Echinaceapurpureaherb
* Kava-Kava root (Pipermethysticum)
* Milk thistle fruit (Silybum marianum)
* Sawpalmetto fruit (Serenoa repens)
* Nettle root (Urticadioica).
One ofthe first dinical trials was performed
with hawthorn extract (Crataegus sp.), which
was standardized on flavonoids and procyani-
dins. It has been suggested that both classes
ofcompounds are the major active principles
and are involved in the positive inotropic and
coronary artery-dilating effect described for
Crataegus extract (10,11). Meanwhile, an
angiotensin-I-converting enzyme (ACE)-
inhibiting effect could be demonstrated for
the oligomeric procyanidins (12. The results
of the trials were accepted by the German
Drug Administration for the treatment of
nondigitalis-dependent patients with heart
insufficiency stage I and II according to the
New York Heart Association. In a double-
blind study of the standardized Crataegus
extract and captopril, the mean score values
ofcomplaints recorded after 8 weeks oftreat-
ment showed the same degree of improve-
ment in both groups (13).
Other trials were performed with the same
positive results, e.g., with standardized Ginkgo,
Hypericum (St. John's wort), Kava-Kava,
Sabal, Urtica, andEchinaceapreparations (1).
Forty-four double-blind studies indicate
the efficacy ofvarious Ginkgo extracts for the
treatment of cognitive disorders. Kleijnen
and Knipschild (14) described eight ofthese
studies and determined that they were per-
formed correctly and without methodologic
shortcomings. A recently published double-
blind study performed with a Ginkgo extract
showed promising results when the extract
was applied for the treatment of dementia
and, in particular, forAlzheimerdisease (15).
The Hypericum extract, which is now
widely used for the treatment of moderate
and less severe depression, was investigated in
several placebo-controlled double-blind
studies (16). Some of these studies were also
performed in parallel with the synthetic psy-
chopharmaceuticals imipramine and maproti-
line (17). Surprisingly, a 6-week treatment
with Hypericum extract with one of the syn-
thetic drugs in parallel resulted in the same
significant reduction of the Hamilton
Depression Anxiety (HAMDA) score values,
with the advantage that there were no side
effects with the Hypericummedication (17).
Another accepted use of herbal drugs
is for the treatment of benign prostatic
hyperplasia. Germans spend approximately
250 million deutsche marks (wholesale price)
per year on prostate remedies, whereas in the
United States, surgical treatment is the gold
standard in urology. In Germany, many urol-
ogists believe that treatment should not target
primarily benign prostatic hyperplasia as such,
but only the associated symptoms, especially
the distressing symptoms of obstructive and
irritative urination (1). In the last 10 years,
many clinical and pharmacologic studies have
confirmed the observations made when
extracts of Urtica root, Serenoa repens fruits
(saw palmetto), Cucurbita pepo (pumpkin)
seeds, and Hypoxis rooperi were used to treat
prostate symptoms (1). The Saba4 Cucurbita,
and Hypoxis drugs; sterins; and other lipids
have been suggested to be responsible for the
antiinflammatory and cell proliferation-
inhibiting effect ofthe extracts. Similar posi-
tive effects observed with Urtica extracts
may be caused by a synergism ofpolar com-
pounds such as UDA and polysaccharides
(18). In recent years, Echinacea preparations
have developed into the best selling herbal
immunostimulants for the adjuvant therapy
ofrecurrent infections ofthe respiratory and
urinary tracts and for the prevention and
therapy of common colds and flu (19).
Thorough phytochemical investigations have
revealed cichoric acid, alkylamides, and poly-
saccharides to be the putative major active
principles responsible for the enhancement
effect on the unspecific immune system (7).
Six clinical studies performed with Echinacea
preparations, reviewed by a meta-analysis,
have confirmed the therapeutic efficacy, but
further investigations are necessary to find
the optimal dosage and application form
(20). The list ofherbal drugs that have been
intensively investigated in the last 10 years by
phytochemists, pharmacologists, and clini-
cians includes Silybum manianum (milk this-
tle), Allium sativum (garlic), Viscum album
(mistletoe), Piper methysticum (Kava-Kava),
Harpagophytum procumbens, Aesculus hip-
pocastanum (horse chestnut), and Valeriana
officinalis. Clinical studies have been per-
formed for thesephytopreparations (1).
Other than the clinical proofofefficacy,
several new scientific findings have arisen
from the many pharmacologic and clinical
investigations that have been performed with
the various phytopreparations. They provide
insight to the mechanism ofaction ofherbal
drugs, which in many respects differs from
that of synthetic drugs. The new findings
can be summarized as follows:
* Phytopreparations are applicable primari-
ly for the treatment ofmoderate or mod-
erately severe diseases. This limitation is
often designated "for stage or grade I and
II" ofany disease. In addition phytoprepa-
rations can also be used as adjuvants in
combination with a strongly acting chemo-
syntheticdrug.
The positive clinical results obtained with
phytopreparations fully justify this type of
classification.
As shown in several comparative clinical
trials (21), several phytopreparations that
were selectedaccording to the above criteria
showed full therapeutic equivalence with
chemotherapeutics and had no adverse
effects.
If one compares the concentrations of the
active compounds of an herbal drug with
those of a strongly acting chemotherapeutic
drug, it is evident that most phytoprepara-
tions exert theireffects at a much lower con-
centration. The ratio can be 1:10 or more.
This difference can be explained by potenti-
atingsynergistic effects causedbythevarious
compounds in a raw herbal drug or extract
when no interactions between the several
compounds are likely or when interactions
can be excluded on the basis ofpharmaco-
logic experiments. The measurement of
synergistic effects can be made with a two-
component mixture ofsubstances according
to the isobol method of Berenbaum (22),
but it is not applicable for herbal extracts.
Therefore, an indirect method using the
results of clinical trials can be used: for
example, if 1 g ofa plant extract containing
a total amount of 1% bioactive compounds
(approximately 10 mg) is found to be ther-
apeutically equivalent to approximately 100
mg ofa synthetic substance at a given equal
indication (as evidenced in a clinical trial),
the bioactive compounds ofthe extract may
possess polyvalent activities and exhibit a
synergistic (potentiating or overadditive)
pharmacologic effect. This conclusion is
justified if the single components of the
bioactive compounds alone have very low
pharmacologic activities. Furthermore, it
must be concluded that the activities ofthe
single components are directed against dif-
ferent pharmacologic targets. In this context,
it should not be assumed that a 5- to 10-fold
potentiation of an overall pharmacologic
effect is caused only by an increased solubii-
ty and by the enhanced oral uptake of the
compounds oftheextractbythegut.
Another phenomenon observed for many
phytopreparations is dose-dependent
pharmacologic ortherapeutic reversal effects
if the same preparations are applied at
high and very low doses. For example, the
cytostatically acting vincristine, which
usually is applied in vivo in milligram con-
centrations, can activate the nonspecific
immune system in minute (microgram or
nanogram) quantities (23).
Many phytopreparations exhibit no imme-
diate pharmacologic or therapeutic effects
and achieve their optimal efficacy only
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after long-term treatment. This effect has
been demonstrated in an in vivostudywith
a Crataegus extract, which resulted in an
increase in myocardial blood circulation
only after a 3-week application (24).
These new findings need a scientific
explanation, especially where the mechanisms
of action and possible interactions are con-
cerned. There is a general consensus that these
described phenomena, which at present have
no rationale, must be elucidated by thorough
and systematic research at a molecular level.
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NIE C"l @ Excellence in basic research at the
National Institute of Environmental Health Sciences
NIEHS scientists and grantees are performing basic studies of our susceptibility to environment-related disease:
demonstrating that a carcinogen in cigarette smoke (benzo[a]pyrene) alters part of a gene to cause lung cancer ...
showing the effects offetal exposure to PCBs . . . developing a strain of mouse that lacks functional estrogen receptors
and that helps evaluate how some pesticides and other estrogen-like compounds might affect development and
reproduction ... discovering the genes for breast, ovarian, and prostate cancers ... identifying women's ..optimal.,:.........
days offertility . .. seeking to reverse the damage from lead exposure ... finding alternatives to tra V
...tests ... pinpointing the functions ofspecific genes by eliminating them from specially bred
5 uing ordinary yeast cells, to isolate and clone genes and other fragments ofgenetic
effects of urban air on lung function...
... ...
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